<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137758</url>
  </required_header>
  <id_info>
    <org_study_id>PCUR101-001</org_study_id>
    <nct_id>NCT03137758</nct_id>
  </id_info>
  <brief_title>A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pellficure Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pellficure Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, non-randomized, Phase I, dose escalation/dose expansion study of
      PCUR-101 in combination with androgen suppression therapy in the patients with metastatic
      CRPC
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities and Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>determined by type and severity using the most recent version of the CTCAE criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>a combination of the revised RECIST 1.1 criteria and the guidelines for Prostate Cancer Working Group 3 (PCWG3) Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities and adverse events</measure>
    <time_frame>up to 2 years</time_frame>
    <description>determined by type and severity using the most recent version of the CTCAE criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Measurement of Serum Cytoine IL-6</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Blood based biomarker</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of Urine Polyamines</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Urine based biomarker</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Metastatic Castration-Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Level 1 (50 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting Dose, 3+3 Cohort Design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 2 (100 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 3 (150 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 4 (200 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 5 (250 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Level 6 (300 mg) PCUR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCUR - 101</intervention_name>
    <description>PCUR-101 Capsules 25 mg are solid dosage forms for oral administration</description>
    <arm_group_label>Level 1 (50 mg) PCUR-101</arm_group_label>
    <arm_group_label>Level 2 (100 mg) PCUR-101</arm_group_label>
    <arm_group_label>Level 3 (150 mg) PCUR-101</arm_group_label>
    <arm_group_label>Level 4 (200 mg) PCUR-101</arm_group_label>
    <arm_group_label>Level 5 (250 mg) PCUR-101</arm_group_label>
    <arm_group_label>Level 6 (300 mg) PCUR-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of metastatic CRPC

          -  standard of care androgen deprivation treatment

          -  castrate serum level of testosterone of ≤ 50 ng/dL (≤ 1.73 mmol/L)

          -  progressive disease while receiving androgen deprivation therapy

          -  previously treated with abiraterone, enzalutamide alone or in combination AND must
             have demonstrated evidence of objective progression as per PCWG3 criteria

          -  adequate hematologic, renal and hepatic function

          -  KPS of ≥ 70 or ECOG of 0 to 1

        Exclusion Criteria:

          -  pure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer
             histology

          -  use of opiate analgesics for prostate cancer pain within 4 week of treatment start

          -  more than one sequential second generation AR-directed therapy

          -  received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12
             weeks or other investigational agents within 4 weeks

          -  history of bleeding disorder

          -  history of seizure disorder

          -  concomitant use of therapeutic anticoagulation

          -  history of or current cardiac issues

          -  received external beam radiation therapy within 4 weeks

          -  CTCAE Grade &gt; 2 neuropathy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Tian</last_name>
      <phone>410-502-5101</phone>
      <email>yantian@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Channing Paller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Wiepz</last_name>
      <phone>608-263-7107</phone>
      <email>wiepz2@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Christos Kyriakopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

